Malignant melanoma is the fastest growing malignancy in the United States (US) in terms of incidence and it currently represents the fifth most common cancer in men and the seventh most common cancer in women. In the US, about 19 men and 14 women per 100,000 population receive a new diagn...
Melanoma is the 5th most common cancer in both males and females in Europe and the United States and remains the most serious form of skin cancer. In a retrospective multicentre DeCOG study,[10] Kahler et al showed that early macular rash within 6 weeks after therapy start was correlated ...
EP: 5.Adjuvant Clinical Trial Data Impact on Treatment Selection EP: 6.Adjuvant Therapy in Stage IIIB/IIIC/IIID Melanoma EP: 7.Balancing Safety and Efficacy in Adjuvant Therapy EP: 8.Short-Term COVID-19 NCCN Recommendations EP: 9.BRAF-Wild Type vs Mutated Unresectable Melanoma EP: 10.Met...
FDA expands approval of nivolumab for melanoma Oral capecitabine was associated with equivalent disease-free survival but greater safety than intravenous bolus fluorouracil plus leucovorin as an adjuvant treatment for stage III colon cancer, reported Chris Twelves, M.D., of the University of Brad-ford...
It is the only drug approved inthe United States for adjuvant therapy of melanoma. It was approved as surgicaladjuvant treatment of patients with a T4 primary (> 4.0 mm in thickness) ornode-positive (stage III) melanoma by the US Food and Drug Administration (FDA)in 1996. It has not ...
5% per year, cutaneous melanoma is an international scourge that disproportionately targets young individuals. Despite much research, the treatment of advanced disease is still quite challenging. Immunotherapy with high-dose interferon-??2b or interleukin-2 benefits a select group of patients in the ...
In conclusion, interferon is the cornerstone of adjuvant therapy in high-risk melanoma today, but the optimal dosage and duration of treatment are still to be defined. Patients with high-risk malignant melanoma should preferentially be treated in prospective randomized multicenter trials to give more ...
Advancing Melanoma Treatment: Hamid on Lifileucel's Role Jordyn Sava;Omid Hamid, MD July 15th 2024 Podcast In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma. ...
1. Surgical intervention is the treatment of choice in patients with melanoma. However, the prognosis for patients with melanoma at stages IIB–IV even after a complete resection is heterogeneous. R...
1-3 As a result, this expansion in indication for ICIs could nearly double the size of the ICI-eligible melanoma population, with more than 8000 additional patients meeting treatment criteria annually.4 Dermatologists, who have historically managed patients with stage IIB/IIC melanoma ...